{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:25:21Z","timestamp":1792218321202,"version":"4.4.0"},"reference-count":173,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1596,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1365-2710.2011.01260.x","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T07:35:29Z","timestamp":1303198529000},"page":"299-326","source":"Crossref","is-referenced-by-count":34,"title":["A review of tumour lysis syndrome with targeted therapies and the role of rasburicase"],"prefix":"10.1155","volume":"36","author":[{"given":"P.","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Qubaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2011,4,19]]},"reference":[{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.12327","article-title":"Tumor lysis syndrome: current perspective","volume":"93","author":"Hochberg","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","article-title":"Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome","volume":"116","author":"Davidson","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2402847","article-title":"Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002","volume":"17","author":"Navolanic","year":"2003","journal-title":"Leukemia"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00280-002-0556-x","article-title":"Acute tumor lysis syndrome in solid tumors - a case report and review of the literature","volume":"51","author":"Baeksgaard","year":"2003","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.clon.2006.09.005","article-title":"Tumour lysis syndrome in solid tumours","volume":"18","author":"Gemici","year":"2006","journal-title":"Clinical Oncology (Royal College of Radiologists (Great Britain))"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0002-9343(97)00153-8","article-title":"Tumor lysis syndrome in small cell carcinoma and other solid tumors","volume":"103","author":"Kalemkerian","year":"1997","journal-title":"American Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1159\/000320581","article-title":"Acute tumor lysis syndrome - a rare complication in the treatment of solid tumors","volume":"33","author":"Coiffier","year":"2010","journal-title":"Onkologie"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10428190903488788","article-title":"Managing tumor lysis syndrome in 2010","volume":"51","author":"Gertz","year":"2010","journal-title":"Leukaemia & Lymphoma"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"British Journal Haematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428190903456959","article-title":"Prognostic significance of acute renal injury in acute tumor lysis syndrome","volume":"51","author":"Darmon","year":"2010","journal-title":"Leukaemia & Lymphoma"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/ndt\/gfp330","article-title":"A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome","volume":"24","author":"Shimada","year":"2009","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/ndt\/14.3.776","article-title":"The spectrum of acute renal failure in tumour lysis syndrome","volume":"14","author":"Haas","year":"1999","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB14|cit14","first-page":"129","article-title":"Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)","volume":"2","author":"Pession","year":"2008","journal-title":"Biologics"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1345\/aph.1C336","article-title":"Rasburicase for the treatment and prevention of hyperuricemia","volume":"37","author":"Yim","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"British Journal Haematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00003495-200666040-00008","article-title":"Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia","volume":"66","author":"Oldfield","year":"2006","journal-title":"Drugs"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3816\/SCT.2005.n.008","article-title":"Optimizing management of tumor lysis syndrome in adults with hematologic malignancies","volume":"2","author":"Michallet","year":"2005","journal-title":"Supportive Cancer Therapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2007-976175","article-title":"Tumor lysis syndrome","volume":"33","author":"Tiu","year":"2007","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood.V104.11.883.883","article-title":"A predictive model for tumor lysis syndrome in acute myelogenous leukemia","volume":"104","author":"Mato","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1200\/jco.2006.24.18_suppl.6577","article-title":"Reproducibility of the Penn predictive score of tumor lysis syndrome (PPS-TLS) in acute myelogenous leukemia (AML)","volume":"24","author":"Mato","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/annonc\/mdh029","article-title":"Renal tubular damage in rasburicase: risks of alkalinisation","volume":"15","author":"van den Berg","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2009.11.001","article-title":"An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome","volume":"36","author":"Mughal","year":"2010","journal-title":"Cancer Treatment Reviews"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00063030-200620030-00008","article-title":"Spotlight on rasburicase in anticancer therapy-induced hyperuricemia","volume":"20","author":"Oldfield","year":"2006","journal-title":"BioDrugs"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14656566.3.4.433","article-title":"Rasburicase: a potent uricolytic agent","volume":"3","author":"Pui","year":"2002","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00277-003-0608-2","article-title":"Incidence of tumor lysis syndrome in children with advanced stage Burkitt\u2019s lymphoma\/leukemia before and after introduction of prophylactic use of urate oxidase","volume":"82","author":"Wossmann","year":"2003","journal-title":"Annals of Hematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/annonc\/mdf134","article-title":"Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d\u2019Oncologie Pediatrique LMB89 protocol","volume":"13","author":"Patte","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","article-title":"Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies","volume":"11","author":"Pui","year":"1997","journal-title":"Leukemia"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1592\/phco.27.1.111","article-title":"Clarifying the role of rasburicase in tumor lysis syndrome","volume":"27","author":"Sood","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone - results of a multicenter phase III study","volume":"28","author":"Cortes","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12185-009-0402-6","article-title":"A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome","volume":"90","author":"Kikuchi","year":"2009","journal-title":"International Journal of Hematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","article-title":"Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin\u2019s lymphoma: results of the GRAAL1 (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Trial on Rasburicase Activity in Adult Lymphoma) study","volume":"21","author":"Coiffier","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl. 4","key":"10.1111\/j.1365-2710.2011.01260.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/bjc.1998.432","article-title":"Advances in the management of malignancy-associated hyperuricaemia","volume":"77","author":"Mahmoud","year":"1998","journal-title":"British Journal of Cancer"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB35|cit35","first-page":"141","article-title":"Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy","volume":"90","author":"Pession","year":"2005","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02893442","article-title":"Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin\u2019s lymphoma","volume":"13","author":"Renyi","year":"2007","journal-title":"Pathology Oncology Research"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000089463","article-title":"Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies","volume":"115","author":"Wang","year":"2006","journal-title":"Acta Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.11612","article-title":"Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study","volume":"98","author":"Bosly","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","article-title":"Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial","volume":"19","author":"Jeha","year":"2005","journal-title":"Leukemia"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/pbc.20555","article-title":"Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea","volume":"46","author":"Shin","year":"2006","journal-title":"Pediatric Blood & Cancer"},{"issue":"Issue 6","key":"10.1111\/j.1365-2710.2011.01260.x-BIB42|cit42","first-page":"CD006945","article-title":"Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer","author":"Cheuk","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1200\/JCO.2008.19.6030","article-title":"Management of tumor lysis syndrome: need for evidence-based guidelines","volume":"26","author":"Feusner","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.2004.99.704","article-title":"Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?","volume":"22","author":"Zaidi","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1200\/JCO.2010.32.6751","article-title":"Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration","volume":"29","author":"Darmon","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3324\/haematol.13290","article-title":"Consensus conference on the management of tumor lysis syndrome","volume":"93","author":"Tosi","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJMct071828","article-title":"BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia","volume":"357","author":"Schiffer","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.leukres.2006.05.005","article-title":"Tumour lysis syndrome with acute renal failure during imatinib therapy","volume":"31","author":"Ali","year":"2007","journal-title":"Leukemia Research"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2710.2009.01035.x","article-title":"Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia","volume":"34","author":"Al-Kali","year":"2009","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB52|cit52","first-page":"510","article-title":"Imatinib-induced tumor lysis syndrome: report of a case and review of the literature","volume":"31","author":"Chang","year":"2008","journal-title":"Chang Gung Medical Journal"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.2002.20.1.354","article-title":"Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"20","author":"Dann","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB54|cit54","article-title":"Rapid clinical improvement and tumor shrinkage following STI571 (Glivec) therapy in a young patient with advanced liver metastases of resected jejunal gastrointestinal stromal tumor (GIST)","volume":"21","author":"Lang","year":"2002","journal-title":"Program\/Proceedings\/American Society of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0609.2008.01186.x","article-title":"Catastrophic tumour lysis syndrome following single dose of imatinib","volume":"82","author":"Keane","year":"2009","journal-title":"European Journal of Haematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ndt\/17.4.685","article-title":"Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571","volume":"17","author":"Kitiyakara","year":"2002","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB57|cit57","doi-asserted-by":"crossref","DOI":"10.1155\/2007\/82012","article-title":"Tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with Glivec (Imatinib Mesylate, Gleevec, STI571)","volume":"2007","author":"Pinder","year":"2007","journal-title":"Sarcoma"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/annonc\/mdf304","article-title":"Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase","volume":"13","author":"Vora","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2710.2008.00873.x","article-title":"Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase","volume":"33","author":"Sonmez","year":"2008","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB61|cit61","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.6520","article-title":"A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase Chronic Myeloid Leukemia (CML): results from CA180002","volume":"23","author":"Sawyers","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB62|cit62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.172.172","article-title":"Dasatinib (Sprycel) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance","volume":"116","author":"Rousselot","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1634\/theoncologist.2009-0088","article-title":"Sorafenib and sunitinib","volume":"14","author":"Kim","year":"2009","journal-title":"Oncologist"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.3748\/wjg.15.4464","article-title":"Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient","volume":"15","author":"Huang","year":"2009","journal-title":"World Journal of Gastroenterology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s10637-009-9275-z","article-title":"Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma","volume":"28","author":"Michels","year":"2010","journal-title":"Investigational New Drugs"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(07)60903-9","article-title":"Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate","volume":"369","author":"Nicholaou","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2007.12.0790","article-title":"Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib","volume":"25","author":"Saylor","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB68|cit68","first-page":"688","article-title":"Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report","volume":"57","author":"Shiozawa","year":"2010","journal-title":"Hepato-Gastroenterology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB69|cit69","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.2518","article-title":"Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia","volume":"26","author":"Foran","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/leu.2010.15","article-title":"Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias","volume":"24","author":"Moore","year":"2010","journal-title":"Leukemia"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB71|cit71","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-03-080689","article-title":"A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","article-title":"Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.thj.6200244","article-title":"Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20","volume":"4","author":"Abou Mourad","year":"2003","journal-title":"The Hematology Journal"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.transproceed.2009.03.060","article-title":"Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder","volume":"41","author":"Francescone","year":"2009","journal-title":"Transplantation Proceedings"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1532\/IJH97.NA0504","article-title":"Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma","volume":"82","author":"Jabr","year":"2005","journal-title":"International Journal of Hematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s002770050419","article-title":"Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)","volume":"77","author":"Jensen","year":"1998","journal-title":"Annals of Hematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11739-008-0099-1","article-title":"Acute tumor lysis syndrome after rituximab administration in Burkitt\u2019s lymphoma","volume":"3","author":"Otrock","year":"2008","journal-title":"Internal and Emergency Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","article-title":"Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia","volume":"62","author":"Yang","year":"1999","journal-title":"American Journal of Hematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3109\/10428190109097760","article-title":"Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis","volume":"42","author":"Kanelli","year":"2001","journal-title":"Leukaemia & Lymphoma"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/156800910790980241","article-title":"Cetuximab: from bench to bedside","volume":"10","author":"Vincenzi","year":"2010","journal-title":"Current Cancer Drug Targets"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2007.14.7603","article-title":"Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB83|cit83","first-page":"105","article-title":"Tumor lysis syndrome secondary to Gemtuzumab Ozogamicin in a patient with acute myelogenous leukemia","volume":"43","author":"Anderson","year":"2002","journal-title":"Journal of the Mississippi State Medical Association"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V83.1.56.56","article-title":"Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma","volume":"83","author":"Minasian","year":"1994","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB85|cit85","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2870.2870","article-title":"Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase Ib study","volume":"114","author":"Agura","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB86|cit86","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2727.2727","article-title":"A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma\/leukemia","volume":"108","author":"Casale","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB87|cit87","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.159.159","article-title":"Complete remissions observed in acute myeloid leukemia following prolonged exposure to SGN-33 (lintuzumab), a humanized monoclonal antibody targeting CD33","volume":"110","author":"Raza","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB88|cit88","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1704.1704","article-title":"Phase I study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+ Non-Hodgkin Lymphoma (NHL)","volume":"114","author":"Salles","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB89|cit89","unstructured":"Welt S Ritter G Cohen L et\u00a0al. 1997 Phase I study of humanized A33 (huA33) antibody in patients with advanced colorectal cancer"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/CCO.0b013e32833d752c","article-title":"Recent advances of IMiDs in cancer therapy","volume":"22","author":"Li","year":"2010","journal-title":"Current Opinion in Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB91|cit91","first-page":"2212","article-title":"Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma","volume":"20","author":"Cany","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mdh116","article-title":"Tumor lysis syndrome in a multiple myeloma treated with thalidomide","volume":"15","author":"Fuente","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.exphem.2006.07.010","article-title":"Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma","volume":"34","author":"Huston","year":"2006","journal-title":"Experimental Hematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.11-1-87","article-title":"Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma","volume":"11","author":"Lee","year":"2006","journal-title":"Oncologist"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB95|cit95","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2007.14.2141","article-title":"Tumor lysis syndrome\/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia","volume":"25","author":"Moutouh-de Parseval","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB96|cit96","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB98|cit98","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia","volume":"26","author":"Andritsos","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB99|cit99","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1200\/JCO.2008.18.2857","article-title":"Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB100|cit100","article-title":"Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response","author":"Chanan-Khan","year":"2010","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB101|cit101","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1395.1395","article-title":"The combination of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"116","author":"Ferrajoli","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB102|cit102","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1679.1679","article-title":"R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed\/refractory indolent Non-Hodgkin\u2019s Lymphoma (NHL)","volume":"114","author":"Dutia","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB103|cit103","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/13543780903002074","article-title":"Clinical development of novel proteasome inhibitors for cancer treatment","volume":"18","author":"Yang","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB104|cit104","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3816\/CLM.2006.n.064","article-title":"Bortezomib-induced tumor lysis syndrome in multiple myeloma","volume":"7","author":"Sezer","year":"2006","journal-title":"Clinical Lymphoma & Myeloma"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB105|cit105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1365-2141.1999.01467.x","article-title":"Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma","volume":"105","author":"Fassas","year":"1999","journal-title":"British Journal Haematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB106|cit106","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-007-0574-9","article-title":"Rapid complete remission in multiple myeloma with bortezomib\/thalidomide\/dexamethasone combination therapy following development of tumor lysis syndrome","volume":"62","author":"Chim","year":"2008","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB107|cit107","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1080\/10428190802484099","article-title":"Bortezomib-associated tumor lysis syndrome in multiple myeloma","volume":"49","author":"Furtado","year":"2008","journal-title":"Leukaemia & Lymphoma"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB108|cit108","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1592\/phco.26.8.1205","article-title":"Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma","volume":"26","author":"Kenealy","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB109|cit109","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1592\/phco.2005.25.12.1820","article-title":"Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia","volume":"25","author":"Jaskiewicz","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB110|cit110","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00432-004-0593-4","article-title":"Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration","volume":"130","author":"Terpos","year":"2004","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB111|cit111","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB112|cit112","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00277-008-0501-0","article-title":"Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1\/2 study after longer follow-up","volume":"87","author":"Berenson","year":"2008","journal-title":"Annals of Hematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB113|cit113","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ar.21218","article-title":"Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China","volume":"293","author":"Chen","year":"2010","journal-title":"Anatomical Record (Hoboken, N.J.: 2007)"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB114|cit114","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.5198.5198","article-title":"Post-marketing surveillance of bortezomib treatment for Multiple Myeloma (MM) in Japan: results of interim analysis by the velcade Japan proper use Guideline Committee","volume":"112","author":"Iida","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB115|cit115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.865.865","article-title":"Initial results of PX-171-004, an open-label, single-arm, phase II study of Carfilzomib (CFZ) in patients with relapsed myeloma","volume":"112","author":"Vij","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB116|cit116","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB117|cit117","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","article-title":"Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease","volume":"27","author":"Lin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB118|cit118","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2009.11.007","article-title":"Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"34","author":"Karp","year":"2010","journal-title":"Leukemia Research"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB119|cit119","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders","volume":"28","author":"Lin","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB120|cit120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB121|cit121","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","article-title":"Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia","volume":"113","author":"Phelps","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB122|cit122","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2009.017103","article-title":"Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias","volume":"95","author":"Blum","year":"2010","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB123|cit123","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2010-09-310862","article-title":"Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias","volume":"117","author":"Karp","year":"2011","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB124|cit124","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma","volume":"28","author":"Tong","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB125|cit125","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2472.2472","article-title":"Phase 1 trial of flavopiridol and lenalidomide in patients with previously treated chronic lymphocytic leukemia","volume":"116","author":"Blum","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB126|cit126","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1396.1396","article-title":"Update on the phase I study of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL): confirmation of clinical activity and feasibility of long-term administration","volume":"116","author":"Flynn","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB127|cit127","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3287.3287","article-title":"Phase II study of the Cyclin-Dependent Kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced acute leukemias","volume":"116","author":"Gojo","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB128|cit128","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-08-2788","article-title":"Epigenetic modifiers: basic understanding and clinical development","volume":"15","author":"Piekarz","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB129|cit129","first-page":"103","article-title":"Clinically significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2B, international, multicenter, registration study","volume":"112","author":"Kim","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB130|cit130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","article-title":"A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia","volume":"81","author":"Gimsing","year":"2008","journal-title":"European Journal of Haematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB131|cit131","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.3324\/haematol.11933","article-title":"Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia","volume":"93","author":"Kalff","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB132|cit132","first-page":"855","article-title":"Oblimersen for the treatment of patients with chronic lymphocytic leukemia","volume":"3","author":"Cheson","year":"2007","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB133|cit133","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia","volume":"23","author":"O\u2019Brien","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB134|cit134","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.4827.4827","article-title":"A pilot study of genasense (oblimersen sodium, Bcl-2 antisense oligonucleotide), fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemia","volume":"104","author":"Chanan-Khan","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB135|cit135","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O\u2019Brien","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB136|cit136","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.3541","article-title":"A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours","volume":"26","author":"Jolivet","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB137|cit137","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/bmj.1.1990.399","article-title":"On the etiology of cancer, with a note of some experiments","volume":"1","author":"Beatson","year":"1899","journal-title":"British Medical Journal"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB138|cit138","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198607243150417","article-title":"Tumor lysis syndrome after tamoxifen flare","volume":"315","author":"Cech","year":"1986","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB139|cit139","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1001\/jama.1978.03290240044022","article-title":"Tamoxifen flare in advanced breast cancer","volume":"240","author":"Plotkin","year":"1978","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB140|cit140","first-page":"112","article-title":"Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report","volume":"16","author":"Zigrossi","year":"2001","journal-title":"Annali Italiani di Medicina Interna"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB141|cit141","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/01.ju.0000115884.21275.f4","article-title":"Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade","volume":"171","author":"Tanvetyanon","year":"2004","journal-title":"Journal of Urology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB142|cit142","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.2830440109","article-title":"Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma","volume":"44","author":"Gold","year":"1993","journal-title":"American Journal of Hematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB143|cit143","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1385\/MO:22:2:203","article-title":"Acute tumor lysis syndrome triggered by zoledronic acid in a patient with metastatic lung adenocarcinoma","volume":"22","author":"Kurt","year":"2005","journal-title":"Medical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB144|cit144","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1200\/JCO.1985.3.5.617","article-title":"Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia","volume":"3","author":"Warrell","year":"1985","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB145|cit145","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB146|cit146","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.3551","article-title":"Phase I evaluation of vascular disrupting agent OXi4503","volume":"26","author":"Patterson","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB147|cit147","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.V112.11.1569.1569","article-title":"Pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multi-center dose-finding trial","volume":"112","author":"Horwitz","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB148|cit148","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB149|cit149","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1345\/aph.1E002","article-title":"Use of single-dose rasburicase in an obese female","volume":"38","author":"Arnold","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB150|cit150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2710.2008.00994.x","article-title":"Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach","volume":"34","author":"Campara","year":"2009","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB151|cit151","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.2010.01457.x","article-title":"A single, fixed dose of rasburicase (6\u2003mg maximum) for treatment of tumor lysis syndrome in adults","volume":"85","author":"Giraldez","year":"2010","journal-title":"European Journal of Haematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB152|cit152","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3816\/SCT.2006.n.016","article-title":"Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome","volume":"3","author":"Ho","year":"2006","journal-title":"Supportive Cancer Therapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB153|cit153","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1600-0609.2007.01013.x","article-title":"Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase","volume":"80","author":"Hummel","year":"2008","journal-title":"European Journal of Haematology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB154|cit154","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1592\/phco.26.2.242","article-title":"Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy","volume":"26","author":"Hutcherson","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB155|cit155","article-title":"Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome","author":"Knoebel","year":"2010","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB156|cit156","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1345\/aph.1D111","article-title":"Treatment of impending tumor lysis with single-dose rasburicase","volume":"37","author":"Lee","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB157|cit157","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.leukres.2004.09.004","article-title":"A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy","volume":"29","author":"Liu","year":"2005","journal-title":"Leukemia Research"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB158|cit158","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.26.6.806","article-title":"Single-dose rasburicase 6\u2003mg in the management of tumor lysis syndrome in adults","volume":"26","author":"McDonnell","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB159|cit159","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1592\/phco.28.6.685","article-title":"Evaluation of a single fixed dose of rasburicase 7.5\u2003mg for the treatment of hyperuricemia in adults with cancer","volume":"28","author":"Reeves","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB160|cit160","first-page":"93","article-title":"Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia","volume":"147","author":"Tarella","year":"2005","journal-title":"Contributions to Nephrology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB161|cit161","article-title":"Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies","author":"Trifilio","year":"2010","journal-title":"Bone Marrow Transplantation"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB162|cit162","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1345\/aph.1P296","article-title":"Fixed-dose rasburicase 6\u2003mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients","volume":"44","author":"Vines","year":"2010","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB163|cit163","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1779.1779","article-title":"Single 4.5\u2003mg dose of rasburicase for tumor lysis syndrome in adults","volume":"116","author":"Yim","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB164|cit164","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V114.22.105.105","article-title":"Randomized clinical trial of rasburicase administered as a standard fixed five days dosing vs a single dose followed by as needed dosing in adult patients with hematologic malignancies at risk for developing tumor lysis syndrome","volume":"114","author":"Vadhan-Raj","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB165|cit165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1042819021000054661","article-title":"Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin\u2019s lymphoma in four European countries","volume":"44","author":"Annemans","year":"2003","journal-title":"Leukaemia & Lymphoma"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB166|cit166","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00520-002-0435-3","article-title":"Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients","volume":"11","author":"Annemans","year":"2003","journal-title":"Supportive Care in Cancer"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB167|cit167","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.2146\/ajhp100022","article-title":"Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients","volume":"67","author":"Eaddy","year":"2010","journal-title":"American Journal of Health System Pharmacy"},{"issue":"Suppl.","key":"10.1111\/j.1365-2710.2011.01260.x-BIB168|cit168","article-title":"The economic implications of rasburicase treatment in adult tumor lysis syndrome patients","volume":"27","author":"Eaddy","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB169|cit169","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1078155209348719","article-title":"Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome","volume":"16","author":"Kennedy","year":"2010","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB170|cit170","article-title":"Acute kidney injury associated with tumor lysis syndrome: a paradigm shift","author":"El-Husseini","year":"2011","journal-title":"American Journal of Emergency Medicine"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB171|cit171","first-page":"1200","article-title":"Pharmacokinetics of intravenous Uricase-PEG 20, a drug for managing hyperuricemia in tumor lysis syndrome","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB172|cit172","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4065\/81.10.1397","article-title":"Tumor lysis syndrome associated with reduced immunosuppression in a lung transplant recipient","volume":"81","author":"Khan","year":"2006","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1111\/j.1365-2710.2011.01260.x-BIB173|cit173","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2010.08506.x","article-title":"Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?","volume":"153","author":"Agrawal","year":"2011","journal-title":"British Journal Haematology"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2011.01260.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2011.01260.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T06:53:15Z","timestamp":1712386395000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2011.01260.x"}},"subtitle":["<i>TLS with targeted therapies and role of rasburicase<\/i>"],"short-title":[],"issued":{"date-parts":[[2011,4,19]]},"references-count":173,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01260.x","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,19]]}}}